Physician profile
Allison Barnes
NPI 1407247877
$2,199.39
in general payments reported to CMS, 2019-2025
30 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $455 · 2023: $684 · 2024: $399 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $377.65 | 2021-2025 | Repatha, Otezla, Prolia |
| Pfizer INC. | $242.07 | 2021-2025 | |
| Lilly USA, LLC | $192.77 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $176.29 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $167.60 | 2021-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.21 | 2021-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $113.61 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Boston Scientific Corporation | $95.74 | 2021-2025 | Varithena Administration Pack, General - Pain Management |
| Medtronic, INC. | $78.39 | 2021-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.29 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $60.38 | 2021-2024 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $56.82 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $54.54 | 2021 | |
| Abbvie INC. | $52.22 | 2022-2025 | |
| Glaxosmithkline, LLC. | $45.82 | 2021-2025 | Shingrix, Arexvy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.65 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $28.42 | 2023 | |
| Smith+Nephew, INC. | $27.58 | 2021-2022 | |
| Vapotherm INC | $25.53 | 2022 | |
| Corcept Therapeutics | $22.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.71 | 2021 | |
| Daiichi Sankyo INC. | $17.18 | 2022 | |
| Merck Sharp & Dohme LLC | $17.08 | 2023 | Verquvo, Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $17.05 | 2022 | |
| Sumitomo Pharma America, INC. | $16.75 | 2024 | Gemtesa |
| Exact Sciences Corporation | $15.99 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $13.43 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $12.38 | 2022 | |
| Clarus Therapeutics INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.